We expect these conditions to remain for theforeseeable future," the company said in a statement. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid(TR-701) in Patients With Complicated Skin and Skin Structure Infections180 Patient Trial of 2nd Generation Oxazolidinone Enrolls in Four Months SAN DIEGO, Jan 26 /PRNewswire/ Trius Therapeutics, Inc. today announcedthe completion of enrollment in its randomized, double-blind Phase 2 clinicaltrial testing the oral dosage form of torezolid (also known as TR-701) inpatients with complicated skin and skin structure infections (cSSSI).Thetrial, which was conducted in 12 clinical sites in the United States, examinedthe efficacy and safety of three dosage strengths of torezolid administeredorally once daily over a 5-7 day course of treatment.Top line results of thePhase 2 trial are expected in the second quarter of this year. "The rapid enrollment in this trial is not only a testimony to the diligenceand competence of our clinical investigators and colleagues, but is also anindicator of the increasing prevalence of bacterial infections caused by MRSAin our hospitals and communities and the potential for an oral drug toconfront this epidemic," said Philippe Prokocimer, M.D., Chief Medical Officerof Trius."Over 90 of the pathogens infecting patients enrolled in our Phase2 trial were Staphylococcus aureus, of which nearly 70 were MRSA. Thecompany's lead drug candidate, torezolid, is a second generation oral and IVoxazolidinone antibiotic with potent activity against drug-resistantGram-positive bacterial pathogens including those resistant to Zyvox(R), theonly marketed antibacterial drug of the oxazolidinone class.Trius haslicensed worldwide rights outside of Korea to torezolid from Dong-APharmaceuticals.Trius' pipeline includes two preclinical programs with leadcandidates being developed to treat serious infections caused by Gram-negativebacterial pathogens.
For more information, visit Therapeutics, Inc.Cathy Yarbrough of Trius Therapeutics, 1-858-243-1814,. ) TD Garden- After playing a solid sixty minute effort last Saturday verses the Hurricanes the Bruins were hoping the momentum would carry into Thursday's battle with the Ducks. First period the Bruins would shoot at all costs but it was Anaheim Hiller that would not give the Bruins any easy goals. But that would change with just under five minutes left in the period Marco Sturm would slip a shot past Hiller giving the Bruins a 1-0 lead into the locker room. Into the second period Bruins up 1-0 and this game would start to slip away. Boston would give Anaheim two powerplays and they would connect on both taking a 2-1 lead. Then the Ducks would connect again on a shorthanded goal and it would be 3-1 Ducks going into the 3rd.
The Bruins had a bit of work to do if they wanted to extend there winning streak. This game would just get worse for the black and gold as the ducks cashed in 3 more goals making it a 6-1 game. Ducks would get two goals fromSelanne and two goals from Perry Also Bobby Ryan and Evgeny Artyukhin would score. The Bruins looking like they did back on October 1st VS the Capitals not much intensity slow to the puck and no connections on the powerplay. The team is hoping that this was just a bad night and that they can pull themselves together before Saturday's tilt vs the Islanders.. TOKYO, Jan 26 (Reuters) - Shin-Etsu Chemical Co (4063.T), theworld's biggest maker of wafers and PVC, posted a 1 percent dropin nine-month profit and declined to disclose an annual profitoutlook due to rapidly declining demand amid the globalrecession.Shin-Etsu, which competes with rival Sumco Corp (3436.T) inthe wafer business, said its net profit came in at 142 billionyen in the April-December period, against 143.4 billion yen ayear earlier. The company did not put out an annual earnings forecast,saying the outlook is unclear.